Literature DB >> 7070216

Tauroursodeoxycholate prevents taurocholate induced cholestasis.

K Kitani, S Kanai.   

Abstract

The nature of transport pathway(s) for the biliary excretion of taurocholate and tauroursodeoxycholate was examined by comparing the biliary transport maximum (Tm) value for taurocholate during the infusion of taurocholate alone with that of taurocholate combined with tauroursodeoxycholate. The combined infusion of tauroursodeoxycholate resulted in an appreciable excretion of tauroursodeoxycholate while the excretion rate of taurocholate was not reduced in comparison with the Tm value of taurocholate alone. Furthermore, the Tm state of taurocholate was maintained for a much longer period with the simultaneous infusion of tauroursodeoxycholate than by the infusion of taurocholate alone. The cholestasis usually produced by the excess infusion of taurocholate was also prevented when tauroursodeoxycholate was simultaneously infused. Since plasma taurocholate concentration was not significantly different from the two rat groups, the results suggest the presence of the facilitative interaction of tauroursodeoxycholate with the taurocholate excretion.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7070216     DOI: 10.1016/0024-3205(82)90264-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  19 in total

1.  The effectual level of ursodeoxycholic acid in therapy for non-advanced chronic cholestasis is fifty percent of total serum bile acids.

Authors:  T Higuchi; N Hishida; T Isomura; H Takeshima; H Hayashi
Journal:  Gastroenterol Jpn       Date:  1992-04

Review 2.  Ursodeoxycholic acid in the treatment of liver diseases.

Authors:  S Saksena; R K Tandon
Journal:  Postgrad Med J       Date:  1997-02       Impact factor: 2.401

Review 3.  The role of cellular hydration in the regulation of cell function.

Authors:  D Häussinger
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

4.  Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis.

Authors:  J Cotting; M J Lentze; J Reichen
Journal:  Gut       Date:  1990-08       Impact factor: 23.059

5.  Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.

Authors:  S Güldütuna; M Leuschner; N Wunderlich; A Nickel; S Bhatti; K Hübner; U Leuschner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Hepatoprotection with tauroursodeoxycholate and beta muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways.

Authors:  P Milkiewicz; M G Roma; E Elias; R Coleman
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

7.  Lithocholate-3-O-glucuronide-induced cholestasis. A study with congenital hyperbilirubinemic rats and effects of ursodeoxycholate conjugates.

Authors:  H Takikawa; K Minagawa; N Sano; M Yamanaka
Journal:  Dig Dis Sci       Date:  1993-08       Impact factor: 3.199

8.  Improvement of cyclosporin A-induced cholestasis by tauroursodeoxycholate in a long-term study in the rat.

Authors:  P E Queneau; P Bertault-Peres; M Guitaoui; E Mesdjian; A Durand; J C Montet
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

9.  Direct, concentration-dependent inhibition by taurocholate of pancreatic exocrine secretion and CCK release in conscious rats.

Authors:  H Tomita; K Miyasaka; M Matsumoto; A Funakoshi
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

10.  Cell volume and bile acid excretion.

Authors:  D Häussinger; C Hallbrucker; N Saha; F Lang; W Gerok
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.